H.C. Wainwright Lifts PT on Innoviva (INVA) to $46 From $45, Keeps a Buy Rating

The standing update came aft Innoviva, Inc. (NASDAQ:INVA) reported the FDA support of NUZOLVENCE® (zoliflodacin) connected December 12, with the steadfast telling investors that zoliflodacin’s support came connected schedule. Zoliflodacin is simply a first-in-class, single-dose, oral antibiotic to dainty uncomplicated urogenital gonorrhea successful adults and pediatric patients 12 years and older weighing astatine slightest 35 kg.

NUZOLVENCE’s improvement was a portion of a not-for-profit, backstage collaboration with the The Global Antibiotic Research and Development Partnership (GARDP), which led and sponsored the Phase 3 objective trial.

Innoviva, Inc. (NASDAQ:INVA) reported that the FDA support was based connected the results from this Phase 3 objective trial, which was the largest ever conducted for a caller attraction against Neisseria gonorrhoeae corruption successful regions with a precocious prevalence of gonorrhea crossed 5 countries. The support makes NUZOLVENCE 1 of the archetypal caller FDA-approved treatments for the information successful astir 2 decades.

Innoviva, Inc. (NASDAQ:INVA) is progressive successful the development, commercialization, and fiscal absorption of biopharmaceuticals.

While we admit the imaginable of INVA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.